Maria Perry
A5071168868- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Epigenetics and DNA Methylation
- Renal cell carcinoma treatment
- Machine Learning in Healthcare
- Hemoglobinopathies and Related Disorders
- Colorectal Cancer Treatments and Studies
- Educator Training and Historical Pedagogy
- Iron Metabolism and Disorders
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Historical Education Studies Worldwide
- Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Lung Cancer Diagnosis and Treatment
- Pharmacological Effects and Toxicity Studies
- Cancer-related gene regulation
- Historical Geopolitical and Social Dynamics
- Histone Deacetylase Inhibitors Research
- Radiomics and Machine Learning in Medical Imaging
Memorial Sloan Kettering Cancer Center
2023-2025
Molecular Oncology (United States)
2024
Kettering University
2024
Massachusetts Institute of Technology
2016
The digitization of health records and growing availability tumour DNA sequencing provide an opportunity to study the determinants cancer outcomes with unprecedented richness. Patient data are often stored in unstructured text siloed datasets. Here we combine natural language processing annotations1,2 structured medication, patient-reported demographic, registry genomic from 24,950 patients at Memorial Sloan Kettering Cancer Center generate a clinicogenomic, harmonized oncologic real-world...
Nearly all pancreatic adenocarcinomas (PDAC) are genomically characterized by KRAS exon 2 mutations. Most patients with PDAC present advanced disease and treated cytotoxic therapy. Genomic biomarkers prognostic of outcomes have been challenging to identify. Herein leveraging a cohort 2,336 spanning stages, we characterize the genomic clinical correlates in PDAC. We show that subtype wild-type tumors is associated early onset, distinct somatic germline features, significantly better overall...
The canonical model of tumor suppressor gene (TSG)-mediated oncogenesis posits that loss both alleles is necessary for inactivation. Here, through allele-specific analysis sequencing data from 48,179 cancer patients, we define the prevalence, selective pressure for, and functional consequences biallelic inactivation across TSGs. TSGs largely assort into distinct classes associated with either pan-cancer (Class 1) or lineage-specific 2) patterns selection loss, although some are predominantly...
513 Background: Isocitrate dehydrogenase 1 and 2 (IDH1/2) play a key role in cellular metabolism epigenetic regulation. Conserved missense IDH1 mutations lead to an accumulation of the onco-metabolite 2-hydroxygluterate, which drives oncogenesis inhibits differentiation. Ivosidenib is now approved for mutant BTC following results phase III ClarIDHy trial. It remains unclear what are long-term outcomes patients (pts) with treated chemotherapy, targeted therapy, immunotherapy. Methods: This...
4170 Background: Adjuvant chemotherapy with mFFX is the standard for pts ECOG 0-1 (1) after pancreatectomy resectable PC. Herein, we report long-term survival data on an expanded cohort and present comprehensive genomic analyses. Methods: Pts resected PC who received >1 dose of adjuvant identified from institutional databases. Primary endpoints: Recurrence Free Survival (mRFS) Overall (mOS) calculated start treatment until recurrence or death. Key secondary clinical factors, descriptors (...
Abstract Background: The majority (~80%) of patients (pts) with pancreatic adenocarcinomas (PDAC) present advanced disease. Most sequencing efforts to date have focused on early stage Herein, we leverage a large clinical cohort N= 2460 pts PDAC characterize the clinico-genomic landscape across different disease stages. Methods: Tumors from were sequenced using MSK-IMPACT assay and mutations called via CLIA-approved pipelines. Detailed descriptors including lines treatment response abstracted...
Abstract Background: The canonical model of tumor suppressor gene (TSG)-mediated oncogenesis, Knudson’s “two hit hypothesis,” posits that loss both alleles is necessary for TSG inactivation. Many key TSGs accordingly exhibit near universal biallelic in associated cancers (e.g., APC colorectal cancer and RB1 retinoblastoma). However, because the majority large-scale genomics studies have utilized non-allele-specific copy number analysis methods, neither extent inactivation across TSGs, nor...
4174 Background: Immune checkpoint blockade (ICB) has limited activity in genomically unselected patients (pts) with PDAC. While anti-tumor combination SABR/ICB been shown, biomarkers of response are poorly defined. We conducted a phase 1/2 study PD-L1 inhibitor Durvalumab (D) and SABR after induction chemotherapy LA BR PDAC (NCT03245541). report long-term outcomes correlative biospecimen analyses. Methods: A multi-institutional, single arm trial was at Cedars-Sinai Memorial Sloan Kettering....
Adjuvant mFOLFIRINOX (mFFX) is standard of care for fit individuals with resected pancreatic ductal adenocarcinoma (PDAC). There are limited data on adjuvant mFFX outcomes outside clinical trials.
<h3>Background</h3> Pancreatic Neuroendocrine Carcinomas (PanNECs) are rare with poor prognosis. Over 70% of cases present as advanced disease<sup>1</sup> and traditionally treated platinum plus etoposide, a regimen extrapolated from small cell lung cancer (SCLC). Pivotal SCLC trials (CASPIAN, IMPOWER133) established improved outcomes in patients (pts) who received combination chemotherapy/immunotherapy (ChemoIO) over chemotherapy alone (Chemo); however, there is limited translation these...
Pain is the most common complication of Sickle Cell Disease (SCD). Tissue oximetry properties in SCD during steady state and acute pain are not well described.This was a cross sectional study tissue individuals with state, healthy controls without SCD. A novel device used to better account for pigmentation interference. We hypothesized that pain, blood volume painful areas would be at least 10% less than state. Bayesian analyses data (with flat piors) were planned priori because small...